FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113451457> ?p ?o ?g. }

• W2113451457 endingPage "404" @default.
• W2113451457 startingPage "393" @default.
• W2113451457 abstract "Preclinical and clinical studies of CYP gene-directed enzyme prodrug therapy have been focused on anticancer prodrugs activated by CYP2B enzymes, which have low endogenous expression in human liver; however, the gene therapeutic potential of CYP3A enzymes, which are highly expressed in human liver, remains unknown. This study investigated methoxymorpholinyl doxorubicin (MMDX; nemorubicin), a novel CYP3A-activated anticancer prodrug. Retroviral transfer of CYP3A4 increased 9L gliosarcoma cell chemosensitivity to MMDX 120-fold (IC50=0.2 nM in 9L/3A4 cells). In CHO cells, overexpression of P450 reductase in combination with CYP3A4 enhanced chemosensitivity to MMDX, and to ifosfamide, another CYP3A4 prodrug, 11- to 23-fold compared with CYP3A4 expression alone. CYP3A4 expression and MMDX chemosensitivity were increased in human lung (A549) and brain (U251) tumor cells infected with replication-defective adenovirus encoding CYP3A4. Coinfection with Onyx-017, a replication-conditional adenovirus that coamplifies and coreplicates the Adeno-3A4 virus, led to large increases in CYP3A4 RNA but only modest increases in CYP3A4 protein and activity. MMDX induced remarkable growth delay of 9L/3A4 tumors, but not the P450-deficient parental 9L tumors, in immunodeficient mice administered low-dose MMDX either intravenous or by direct intratumoral (i.t.) injection (60 μg kg−1, every 7 days × 3). Notably, the i.t. route was substantially less toxic to the mouse host. No antitumor activity was observed with intraperitoneal MMDX treatment, suggesting a substantial hepatic first pass effect, with activated MMDX metabolites formed in the liver having poor access to the tumor site. These studies demonstrate that human CYP3A4 has strong potential for MMDX prodrug-activation therapy and suggest that endogenous tumor cell expression of CYP3A4, and not hepatic CYP3A4 activity, is a key determinant of responsiveness to MMDX therapy in cancer patients in vivo." @default.
• W2113451457 created "2016-06-24" @default.
• W2113451457 creator A5044985980 @default.
• W2113451457 creator A5068046399 @default.
• W2113451457 creator A5089951899 @default.
• W2113451457 date "2008-11-14" @default.
• W2113451457 modified "2023-10-07" @default.
• W2113451457 title "Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer" @default.
• W2113451457 cites W1823015855 @default.
• W2113451457 cites W1964387224 @default.
• W2113451457 cites W1965951315 @default.
• W2113451457 cites W1967325600 @default.
• W2113451457 cites W1992703558 @default.
• W2113451457 cites W2005036141 @default.
• W2113451457 cites W2006774917 @default.
• W2113451457 cites W2011914389 @default.
• W2113451457 cites W2013715004 @default.
• W2113451457 cites W201548973 @default.
• W2113451457 cites W2021115756 @default.
• W2113451457 cites W2023038363 @default.
• W2113451457 cites W2031638389 @default.
• W2113451457 cites W2036589843 @default.
• W2113451457 cites W2047359668 @default.
• W2113451457 cites W2051894324 @default.
• W2113451457 cites W2054319806 @default.
• W2113451457 cites W2056793490 @default.
• W2113451457 cites W2059197648 @default.
• W2113451457 cites W2066324183 @default.
• W2113451457 cites W2074769373 @default.
• W2113451457 cites W2076379144 @default.
• W2113451457 cites W2082242105 @default.
• W2113451457 cites W2086560868 @default.
• W2113451457 cites W2090090086 @default.
• W2113451457 cites W2094764170 @default.
• W2113451457 cites W2102236923 @default.
• W2113451457 cites W2106570139 @default.
• W2113451457 cites W2109963256 @default.
• W2113451457 cites W2117917400 @default.
• W2113451457 cites W2120482363 @default.
• W2113451457 cites W2122669405 @default.
• W2113451457 cites W2124758388 @default.
• W2113451457 cites W2130054191 @default.
• W2113451457 cites W2130482724 @default.
• W2113451457 cites W2131527543 @default.
• W2113451457 cites W2135761785 @default.
• W2113451457 cites W2147995447 @default.
• W2113451457 cites W2152113080 @default.
• W2113451457 cites W2154128645 @default.
• W2113451457 cites W2159813540 @default.
• W2113451457 cites W2163801438 @default.
• W2113451457 cites W79275981 @default.
• W2113451457 doi "https://doi.org/10.1038/cgt.2008.93" @default.
• W2113451457 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2669851" @default.
• W2113451457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19011599" @default.
• W2113451457 hasPublicationYear "2008" @default.
• W2113451457 type Work @default.
• W2113451457 sameAs 2113451457 @default.
• W2113451457 citedByCount "22" @default.
• W2113451457 countsByYear W21134514572012 @default.
• W2113451457 countsByYear W21134514572013 @default.
• W2113451457 countsByYear W21134514572014 @default.
• W2113451457 countsByYear W21134514572015 @default.
• W2113451457 countsByYear W21134514572016 @default.
• W2113451457 countsByYear W21134514572018 @default.
• W2113451457 countsByYear W21134514572020 @default.
• W2113451457 countsByYear W21134514572022 @default.
• W2113451457 crossrefType "journal-article" @default.
• W2113451457 hasAuthorship W2113451457A5044985980 @default.
• W2113451457 hasAuthorship W2113451457A5068046399 @default.
• W2113451457 hasAuthorship W2113451457A5089951899 @default.
• W2113451457 hasBestOaLocation W21134514572 @default.
• W2113451457 hasConcept C104317684 @default.
• W2113451457 hasConcept C108215921 @default.
• W2113451457 hasConcept C109650736 @default.
• W2113451457 hasConcept C111599444 @default.
• W2113451457 hasConcept C150903083 @default.
• W2113451457 hasConcept C153911025 @default.
• W2113451457 hasConcept C181199279 @default.
• W2113451457 hasConcept C185592680 @default.
• W2113451457 hasConcept C207001950 @default.
• W2113451457 hasConcept C2776694085 @default.
• W2113451457 hasConcept C2781303535 @default.
• W2113451457 hasConcept C502942594 @default.
• W2113451457 hasConcept C526171541 @default.
• W2113451457 hasConcept C54009773 @default.
• W2113451457 hasConcept C54355233 @default.
• W2113451457 hasConcept C55493867 @default.
• W2113451457 hasConcept C86803240 @default.
• W2113451457 hasConcept C98274493 @default.
• W2113451457 hasConceptScore W2113451457C104317684 @default.
• W2113451457 hasConceptScore W2113451457C108215921 @default.
• W2113451457 hasConceptScore W2113451457C109650736 @default.
• W2113451457 hasConceptScore W2113451457C111599444 @default.
• W2113451457 hasConceptScore W2113451457C150903083 @default.
• W2113451457 hasConceptScore W2113451457C153911025 @default.
• W2113451457 hasConceptScore W2113451457C181199279 @default.
• W2113451457 hasConceptScore W2113451457C185592680 @default.
• W2113451457 hasConceptScore W2113451457C207001950 @default.

• next